Biovie (BIVI) Operating Expenses (2013 - 2026)
Biovie (BIVI) posted Operating Expenses of $5.4 million for Q1 2026, down 14.0% sequentially from $6.3 million in Q4 2025, and up 80.22% YoY from $3.0 million in Q1 2025.
Biovie (BIVI) Operating Expenses (2013 - 2026) Analysis & Trends
Biovie has reported Operating Expenses for 13 years, with the latest figure at $5.4 million in Q1 2026.
- Quarterly Operating Expenses rose 80.22% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.6 million (up 7.3% YoY) and the FY2025 annual result came in at $18.1 million, down 43.86% from the prior year.
- Operating Expenses declined to $5.4 million in Q1 2026 per BIVI's latest filing, from $6.3 million in the prior quarter.
- Over five years, Operating Expenses peaked at $13.8 million in Q1 2023 and troughed at $3.0 million in Q1 2025.
- A 5-year average of $7.5 million and a median of $7.3 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses plunged 92.94% in 2022, then jumped 139.61% in 2023.
- Over 5 years, Operating Expenses stood at $11.5 million in 2022, then declined by 23.61% to $8.8 million in 2023, then fell by 16.95% to $7.3 million in 2024, then slipped by 14.13% to $6.3 million in 2025, then slipped by 14.0% to $5.4 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $5.4 million, $6.3 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | 5.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.72 Mn |
| Mar 31, 2026 | 5.39 Mn |
| Dec 31, 2025 | 6.26 Mn |
| Sep 30, 2025 | 5.28 Mn |
| Jun 30, 2025 | 3.66 Mn |
| Mar 31, 2025 | 2.99 Mn |
| Dec 31, 2024 | 7.29 Mn |
| Sep 30, 2024 | 4.12 Mn |
| Jun 30, 2024 | 4.79 Mn |
| Mar 31, 2024 | 7.73 Mn |
| Dec 31, 2023 | 8.78 Mn |
| Sep 30, 2023 | 10.88 Mn |
| Jun 30, 2023 | 10.98 Mn |
| Mar 31, 2023 | 13.77 Mn |
| Dec 31, 2022 | 11.49 Mn |
| Sep 30, 2022 | 8.83 Mn |
| Jun 30, 2022 | 9.29 Mn |
| Mar 31, 2022 | 5.75 Mn |
| Dec 31, 2021 | 6.67 Mn |
| Sep 30, 2021 | 5.55 Mn |